Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Fosun International Limited    0656   HK0656038673

FOSUN INTERNATIONAL LIMITED

(0656)
  Report  
End-of-day quote. End-of-day quote Stock Exchange of Hong Kong - 09/20
10.46 HKD   0.00%
09/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/20FOSUN INTERNATIONAL : Tour operator Thomas Cook in race to avoid bankruptcy
AQ
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Fosun : INSIDE INFORMATION AND JOINT PROGRESS ANNOUNCEMENT — DISCLOSEABLE TRANSACTION — INTELLECTUAL PROPERTY,DEVELOPMENT & COMMERCIALIZATION TRANSFER AGREEMENTS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/30/2014 | 03:33pm EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of

China with limited liability)

(Stock Code: 02196)

INSIDE INFORMATION AND

JOINT PROGRESS ANNOUNCEMENT

DISCLOSEABLE TRANSACTION - INTELLECTUAL PROPERTY,

DEVELOPMENT & COMMERCIALIZATION TRANSFER AGREEMENTS

This joint announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (''Fosun Pharma'') and Fosun International Limited (''Fosun International'') pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance.
References are made to the joint announcements of Fosun Pharma and Fosun International dated 18
October 2013 and 23 October 2013 (the ''Joint Announcements'') in relation to, among other things, the intellectual property, development & commercialization transfer agreements. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the Joint Announcements.
Pursuant to the Transfer Agreements dated 23 October 2013, Chongqing Fochon, an indirectly-owned subsidiary of Fosun Pharma agreed to sell and transfer, and SELLAS Clinicals Holding AG as the Purchaser, agreed to purchase all of Chongqing Fochon's and its wholly-owned subsidiaries' right, title and interest in the Intellectual Property in respect of Fotagliptin Benzoate and Pan-HER inhibitors for an estimated total consideration of approximately EUR388 million. The consideration is payable in several stages and as at the date of this announcement, the accumulated consideration payable by the Purchaser amounted to EUR8 million, with the actual paid consideration amounted to EUR1.5 million.
As the Purchaser has failed to timely perform its payment obligations under the Transfer Agreements, and pay the balance of the consideration due and payable upon reasonable notices and requests made by Chongqing Fochon, on 30 June 2014, Chongqing Fochon notified the Purchaser in writing that the Transfer Agreements be terminated pursuant to the terms of the Transfer Agreements. Chongqing Fochon reserves its right to claim against the Purchaser in respect of any and all losses, damages, costs and expenses which may be suffered or incurred by Chongqing Fochon arising from the termination of the Transfer Agreements as a result of the default of the Purchaser.

- 1 -

Both the Boards of Fosun Pharma and Fosun International are of the view that the termination of the Transfer Agreements will not have any material adverse effect on the financial position and operation of Fosun Pharma and its subsidiaries.
By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu
Chairman
By order of the Board
Fosun International Limited
Guo Guangchang
Chairman
Shanghai, PRC
30 June 2014

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of Fosun Pharma are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of Fosun Pharma are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Ding Guoqi, Mr. Qin Xuetang and Mr. Wu Ping; the non-executive director of Fosun International is Mr. Fan Wei, and the independent non-executive directors of Fosun International are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.

* for identification purposes only

- 2 -

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FOSUN INTERNATIONAL LIMITE
09/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/20NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/20FOSUN INTERNATIONAL : Tour operator Thomas Cook in race to avoid bankruptcy
AQ
09/18FOSUN INTERNATIONAL : Joint announcement - the proposed spin-off and separate li..
PU
09/18China's Henlius raises $410 million in Hong Kong IPO - sources
RE
09/16FOSUN INTERNATIONAL : Thomas Cook is in scramble to seal rescue deal
AQ
09/12FOSUN INTERNATIONAL : Letter to registered holders - notification letter and cha..
PU
09/11FOSUN INTERNATIONAL : Joint announcement - the proposed spin-off and separate li..
PU
09/10Henlius Biotech launches $477 million HK IPO, testing market amid protests
RE
09/10FOSUN INTERNATIONAL : Joint announcement - the proposed spin-off and separate li..
PU
More news
Financials (CNY)
Sales 2019 121 B
EBIT 2019 26 591 M
Net income 2019 14 946 M
Debt 2019 71 691 M
Yield 2019 3,81%
P/E ratio 2019 5,29x
P/E ratio 2020 4,90x
EV / Sales2019 1,26x
EV / Sales2020 1,35x
Capitalization 80 842 M
Chart FOSUN INTERNATIONAL LIMITED
Duration : Period :
Fosun International Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FOSUN INTERNATIONAL LIMITE
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 14,44  CNY
Last Close Price 9,46  CNY
Spread / Highest target 80,1%
Spread / Average Target 52,6%
Spread / Lowest Target 13,6%
EPS Revisions
Managers
NameTitle
Qun Bin Wang Chief Executive Officer & Executive Director
Qi Yu Chen Co-President & Executive Director
Xiao Liang Xu Co-President & Executive Director
Guang Chang Guo Chairman
Can Wang Chief Financial Officer, Executive Director & SVP
Sector and Competitors
1st jan.Capitalization (M$)
FOSUN INTERNATIONAL LIMITED-8.57%11 399
ALLIANZ SE21.02%97 058
CHUBB LTD22.06%71 863
ZURICH INSURANCE GROUP30.13%55 655
MARSH & MCLENNAN COMPANIES28.20%51 087
AMERICAN INTERNATIONAL GROUP INC45.78%49 976